Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 11/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339748 | 0.91 | NTRK1 (0.43) | NTRK1NTRK3NTRK2GABBR2GABBR1 | |
| SCHEMBL2207310 | 0.85 | APP (0.46) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1164979 | 0.82 | PAK4 (0.46) | NTRK1 | |
| SCHEMBL3547401 | 0.81 | PDE5A (0.46) | — | |
| SCHEMBL3767642 | 0.80 | PAK4 (0.36) | NTRK1GABBR2GABBR1 | |
| SCHEMBL4517729 | 0.76 | PAK1 (0.44) | NTRK2CYP1A2CYP2C9CYP2C19AURKB | |
| SCHEMBL4068340 | 0.76 | — | — | |
| SCHEMBL3341895 | 0.75 | ABCG2 (0.38) | CYP1A2 | |
| SCHEMBL3755800 | 0.75 | DRD2 (0.31) | — | |
| SCHEMBL588427 | 0.75 | KMT2A (0.47) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | NTRK1 7/4885NTRK3 12/4885NTRK2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.